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Abstract
Background: The chemopreventive effects of resveratrol (RSV) on prostate cancer have been well established; the androgen
receptor (AR) plays pivotal roles in prostatic tumorigenesis. However, the exact underlying molecular mechanisms about the
effects of RSV on AR have not been fully elucidated. A model system is needed to determine whether and how RSV
represses AR transcriptional activity.
Methodology: The AR cDNA was first cloned into the retroviral vector pOZ-N and then integrated into the genome of AR-
negative HeLa cells to generate the AR(+) cells. The constitutively expressed AR was characterized by monitoring hormone-
stimulated nuclear translocation, DNA binding, and transcriptional activation, with the AR(-) cells serving as controls. AR(+)
cells were treated with RSV, and both AR protein levels and AR transcriptional activity were measured simultaneously.
Chromatin immunoprecipitation (ChIP) assays were used to detect the effects of RSV on the recruitment of AR to its cognate
element (ARE).
Results: AR in the AR (+) stable cell line functions in a manner similar to that of endogenously expressed AR. Using this
model system we clearly demonstrated that RSV represses AR transcriptional activity independently of any effects on AR
protein levels. However, neither the hormone-mediated nucleus translocation nor the AR/ARE interaction was affected by
RSV treatment.
Conclusion: We demonstrated unambiguously that RSV regulates AR target gene expression, at least in part, by repressing
AR transcriptional activity. Repressive effects of RSV on AR activity result from mechanisms other than the affects of AR
nuclear translocation or DNA binding.
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Introduction
Prostate cancer is one of the biggest threats to men’s health in
the western world and it accounts for the second largest number of
male cancer deaths in the United States [1,2]. Although hormone
therapy benefits about 80% of patients by retarding the
progression of the disease [3], almost all prostate cancers
eventually develop into an aggressive, hormone-independent
form, with little hope for further intervention [4]. Therefore, the
best approach for combating prostate cancer is preventing its
occurrence in the first place. This makes chemoprevention an
attractive approach. In addition, high-grade prostatic intraepithe-
lial neoplasia develops over a period of around twenty years, and
the progression to clinically significant carcinoma may take
another thirteen to fifteen years [5]. Since it usually takes some
time for the chemopreventive effects to be observable, the long
latency periods make prostate cancer one of the best model
systems in chemoprevention studies [6].
Androgen is an important regulator of prostate gland develop-
ment and function, including proliferation, differentiation, main-
tenance [7], and it is also essential in the process of prostatic
carcinogenesis [8]. The androgen receptor (AR) is a crucial
mediator of androgen action and a ligand-dependent transcription
factor that belongs to the nuclear steroid hormone receptor super-
family [9,10]. Similar to other steroid receptors, AR contains an
amino-terminal activation functional domain (AF1) that affects
transcription efficiency; a central DNA-binding domain (DBD),
which mediates receptor binding to specific DNA sequences in the
promoter/enhancer regions of the target genes; and C-terminal
ligand binding domain (LBD) which also contains another
activation functional domain (AF2). Without ligand binding, the
AR mainly resides in the cytoplasm and complexes with heat-
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shock proteins. When bound to hormones, the receptor undergoes
conformational changes, dissociates from heat shock proteins and
translocates to the nucleus. In the nucleus, the AR binds to a
specific DNA sequence known as an androgen responsive element
(ARE), where it initiates the recruitment of specific co-regulators
and mediators to form transcription complexes and regulate the
transcription of AR target genes. Combinations of AR target gene
expressions determine the fate of the cell [8]. AR plays pivotal
roles not only in prostate cancer initiation, but also in its
progression and even in the hormone-independent stages. AR
and prostate specific antigen (PSA), the utmost useful biological
maker of prostate cancer, express continuously in hormone-
independent prostate cancers [11]. In fact, multiple line of
evidence shown that the AR signaling system remains functional
in the hormone-independent stages with different mechanisms
such as AR mutation, amplification and modifications [12]. In
addition, changes in AR coactivator and co-repressor ratios are
implicated in these stages [13]. Therefore, the development of
novel and more effective treatments targeting AR and AR-related
molecules will be a plausible strategy in combating both androgen-
dependent and androgen-independent prostate cancers [12].
Environmental factors, including nutritional and dietary factors,
play fundamental roles in the development of prostatic cancer as
well as other cancers [6,14]. It has been estimated that up to thirty to
fifty percent of all cancers could be prevented by attention to dietary
factors [15]. Thus far, different dietary factors including selenium,
vitamin E, lycopene, resveratrol (RSV), and other anti-androgen
reagents have been considered as potential prostate cancer
chemopreventive agents [16,17]. RSV (3,49,5-trihydroxystilbene),
one of the well documented agents in prostate cancer chemopre-
vention [18], is a polyphenol transhydroxystilbene found at high
levels in grapes and red wines [19,20]. Animal studies have
demonstrated that RSV is rapidly absorbed by the gut and shows
excellent tissue bioavailability [21–23]. Since the first reported
cancer chemopreventive effects of RSV in 1997 [24], both
epidemiological and case controlled studies have demonstrated that
RSV and/or consumption of high RSV-containing foods and drinks
can reduce prostate cancer incidences [25]. But the exact
underlying molecular mechanisms for each effect are largely
unknown. There are lines of evidence shown that RSV exerts its
effects on prostate cancer in a AR-independent manner [26–28],
due to the pivotal role of AR in prostate cancer development, special
attention has been paid to the effects of RSV on AR. It has been well
established that the chemopreventive effects of RSV on prostate
cancer involves its regulation of AR expression and function
[29,30]. Using microarray and other techniques, it has been well
established that RSV down regulates the expressions of both AR
and AR target genes [31–33]. Gao et al found that RSV effects on
AR activity are concentration dependent; AR activity is enhanced at
low concentration of RSV and is repressed at high concentrations
[34]. Harada et al reported recently that RSV represses AR target
gene expression, at least partially, by enhancing AR degradation in
a time- and dose-dependent manner [35].
As a first step elucidating the molecular mechanisms of the
chemopreventive effects of RSV on prostate cancer development,
experiments were designed to clarify whether RSV regulates AR
target gene expression by repressing AR transcriptional activity. For
this purpose, AR cDNA was integrated into the genome of the AR-
negative HeLa cell line to make an AR-positive cell line, AR(+), in
which the expression of AR is not affected by RSV. Since AR is
constitutively expressed in AR(+) cells, this enables us to specifically
analyze the repressive effects of RSV on AR transcriptional activity.
The AR-negative cell line, AR(-), was established by infecting the
same parental HeLa cells with empty vector DNA and serves as a
control. With this system, we demonstrated that RSV regulates AR
target gene expression, at least in part, by repressing AR
transcriptional activity. Further, we show that the repressive effects
of RSV on AR transcriptional activity are not due to changes in
nuclear translocation or DNA binding.
Materials and Methods
Chemicals, cells and Cell Culture
Resveratrol was purchased from Sigma (St. Louis, MO) and a
stock solution (1 mM) was made by dissolving RSV in DMSO
(Sigma, St. Louis, MO). The solution was stored at 220uC in the
dark. The synthetic androgen R1881 was purchased from Sigma
Inc. and dissolved in ethanol to make a stock solution (10 mM).
AR antibodies N-20 and N-19 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-Flag antibody was pur-
chased from Sigma (St. Louis, MO). The PSA-enhancer-Luc
reporter, containing a 6.1 kb DNA fragment corresponding to the
human PSA enhance plus promoter [36], and the pOZ-N vector
were obtained from Dr. Jiemin Wong (Baylor College of Medicine,
Houston, TX). Tissue culture media were purchased from
Invitrogen Inc. LNCaP and HeLa cell lines were obtained from
American Type Culture Collection (ATCC).
The LNCaP cells were maintained in RPMI 1640 medium
supplemented with 10% (wt/vol) fetal bovine serum (FBS) and 1%
antibiotics at 37uC under 5% CO2. For treatment with either
agonists or antagonists, LNCaP cells were culture in phenol red-free
RPMI 1640 medium with 10% charcoal-stripped FBS and 1%
antibiotics at 37uC under 5%CO2 for at least 3 days. After this, cells
were incubated in fresh medium containing charcoal-stripped FBS
supplemented with either 10 nM of the synthetic androgen R1881
or different concentrations of RSV for the specific time periods.
AR(+) and AR(-) cells were maintained in DMEM with 10% FBS
1% antibiotics at 37uC under 5% CO2. For treatments, the cells
were also transferred and kept in phenol red-free medium with
charcoal-stripped FBS for 3 days before addition of either androgen
agonist or RSV. Since the androgen agonists and antagonists were
dissolved in ethanol and RSV was dissolved in DMSO, corre-
sponding amounts of ethanol or DMSO were added to cells in
separate dishes to serve as negative controls of treatments.
Generation of AR(+) cell line
Human AR was amplified by PCR with AR-specific primers
flanking the open reading frame (ORF). For cloning purposes, the
restriction sites XhoI and BamHI were added to the 59- and 39-
primer, respectively. Both the amplified AR and the retroviral
pOZ-N vector were digested with XhoI and BamHI and the AR
was cloned downstream of the Flag-epitope. DNA sequencing was
conducted to assure that the AR was correctly inserted in the
vector. The pOZ-N retroviral vector expresses a bicistronic
mRNA encoding the Flag and therefore the Flag-tagged AR is
expressed. The virus DNA was transfected into 293T cells using
FuGene 6 Transfection Reagent (Roche Diagnostics Corporation,
IN). Packaged viruses were collected from the transfected 293T
cells, filtered through a 0.45 um filter, and used to infect AR-
negative HeLa cells. The transduced cells also express interleukin-
2 receptor subunit (IL-2R, Figure 1A) which serves as surface
marker for cell sorting [37] using the magnetic Dynabeads M-450
(DYNAL, NY) coated with IL-2R antibodies. Empty pOZ-N
vector DNA was used to generate the AR(-) controls.
Immunostaining
Immunostatining was performed as previously reported [38].
Cells were grown on glass cover slides, fixed with 3.5%
Resveratrol, AR and Cancer
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formaldehyde for 15 minutes, and permeabilized with 0.02%NP-40
for 1 minute. After blocking with 5% goat serum for 1 hour, cells
were incubated with either anti-Flag or anti-AR antibodies for
2 hours. The slides were then incubated in donkey anti-rabbit
immunoglobin G conjugated with Alexa Fluor 594 for 2 hours. One
drop of mounting medium (Fisher Scientific) was added onto each
slide and the images were visualized by conventional microscopy.
Transfection and luciferase assay
A luciferase reporter construct containing the PSA-enhancer
region was transiently transfected into cells using Lipofectamine
2000 reagent according to the manufacturer’s instructions
(Invitrogen). Transfected cells were allowed to recover for 6 hours
before the R1881 and/or RSV were added, and were then grown
overnight. Cells were harvested and lysed in Luciferase Lysate
Buffer (Promega) and luciferase activities were measured by
Luminometer. All experiments were conducted in triplicate.
RNA isolation and RT-PCR
Total RNA was isolated using the RNeasy mini kit (Qiagen),
according to the manufacturer’s specifications. Total RNA from
each sample was reverse-transcribed with random primers using a
StrataScript reverse transcriptase kit (Stratagene) followed by either
semi-quantitative or real-time PCR. Our standard PCR procedures
are as follows: In a 25 ul of reaction, DNAwas denatured at 94uC for
2 min and followed by 30 cycles of 94uC for 45 sec, 62uC for 45 sec
and 72uC for 45 sec. After the last cycle, reactions were incubated for
an additional 5 min at 72uC to ensure that all DNA strands were
extended to the ends. PCR products were separated by electropho-
resis on 1% agarose gel and visualized under UV light. The
intensities of DNA bands were estimated by the Image-J program.
Preparation of Lysates and Western Blot
Whole cell lysates, cytoplasmic and nuclear extracts were obtained
using the nuclear extract kit (Active Motif, California) according the
manufacturer’s instructions. Protein concentrations were estimated
by Bradford reagents and equal amounts of total proteins were
separated on a 7.5% SDS-PAGE gel. The proteins were transferred
to nitrocellulose membrane (BioRad, Hercules, CA) using the
BioRad Blotting System according to the manufacturer’s instructions.
Staining with Ponceau Red was done to confirm equal transfer of
protein in all lanes. Blots were blocked for 2 hours in 5% non-fat milk
and incubated with antiserum overnight at 4uC. After washing three
times in TBST, the blot was incubated with the second conjugated
antibody. The blot was detected by Supersignal West Pico
Chemiluminescent Kit (Pierce). The same membrane was stripped
and re-probed for either b-actin or GAPDH as internal controls.
Chromatin immunoprecipitation (ChIP) Assays
ChIP assays were conducted as described previously [38,39]. In
brief, approximately 26109 cells in 150 mm dishes were first treated
with PBS containing 1% formaldehyde for 10 min, washed twice
Figure 1. Establishment and verification of AR(+) cell line. (A) Human AR cDNA was first amplified using specific PCR primers with XhoI and
BamHI restriction sites added to the 59- and 39- primers, respectively. The digested AR open reading frame was inserted into the mammalian
expression vector pOZ-N behind the FLAG tag. The interleukin-2 receptor subunit, which is expressed and responsible for the affinity purification, was
shown as IL-2R. (B) Whole cell lystates from AR(+) and AR(2) cells were separated by electrophoresis on a SDS-PAGE and the FLAG-tagged AR were
detected with either anti-FLAG (upper panel) or anti-AR (bottom panel) antibodies. Anti-actin antibodies were used on the same blots to
demonstrate equal protein loadings.
doi:10.1371/journal.pone.0007398.g001
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with cold PBS, and incubated with 100 mM Tris-HCl (pH 9.4)/
10 mMDTT at 30u for 20 min. The cells are then rinsed twice with
cold PBS and re-suspended in 600 ml of Buffer A (10 mM HEPES
[pH 7.9], 0.5% NP-40, 1.5 mM MgCl2, 10 mM DTT) by
pipetting. After a brief spinning, the pellets are re-suspended in
Buffer B (20 mM HEPES [pH 7.9], 25% glycerol, 0.5% NP-40,
0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA) containing
protease inhibitors by vigorous pipetting. After centrifugation at
4000 rpm for 5 min, the nuclear pellets were resuspended in Buffer
C (1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.0],
150 mM NaCl) with freshly added protease inhibitors. The nuclear
lysates were then sonicated to break the chromatin into fragments
with average lengths of 0.5–1.5 kb. Immunoprecipitation was then
conducted by adding specific antibodies. Equal amounts of rabbit or
mouse normal IgG were used as negative controls for polyclonal and
monoclonal antibodies, respectively. Precipitated DNA was used as
a template for PCR amplification with primers specific to the
promoter region of PSA gene. Forward primer, 59-
TGCCAGGGCCTATTTTGAATC-39. Reverse primer is 59-
AGAGCCTGAGTGAAGACCCATAAG-39. The PCR condi-
tions were as described above.
Results
Effects of RSV on prostate cancer cell LNCaP
The general theme of RSV’s effects is that this phytochemical,
similar to other dietary components with chemopreventive effects,
inhibits cancer cell growth and enhances apoptosis [40,41]. To
demonstrate RSV’s effects on prostate cancer, such as with growth
inhibition or apoptosis enhancement, we treated the hormone-
dependent prostate cancer cell line LNCaP with different
concentrations of RSV. As shown in Figure 1A, equal numbers
of cells were seeded in growth medium containing 10 nM R1881,
and different concentrations of RSV, as indicated. After 3 days of
treatment, cells were collected and cell numbers were determined.
The number of cells in the control plate (0 mM RSV) was set as
100% and the numbers of cells in the plates treated with different
RSV concentrations (0 to 150 mM) were expressed as percentage
of the control. The experiment was conducted in triplicate and the
averages were plotted and shown in Figure 1A. It clearly
demonstrates that the effects of RSV on LNCaP cell growth
and/or apoptosis are dose-dependent and this is consistent with
other reported results [31]. Of note, the cells treated with 150 mM
RSV appeared to be unhealthy and many dead cells were seen,
presumably due to the necrotic effects of RSV [42].
LNCaP cells are AR-positive, androgen-responsive cells and RSV
has been shown to affect both AR and AR target gene expression in
these cells [32]. We decided to monitor the mRNA levels of AR and
one of its target genes, prostate specific antigen (PSA), during RSV
treatment. Since it has been reported [32] and demonstrated above
(figure 1A) that effects of RSV on LNCaP cells are dose-dependent,
we chose to use the moderate concentration (50 uM) of RSV
treatment. Total RNA was purified from cells treated with 50 mM of
RSV for 3 days. AR and PSA mRNA levels were estimated by RT-
PCR. In order to increase the accuracy of the measurements, the
internal control GAPDH was amplified in the same PCR reaction as
the gene of interest. As shown in Figure 1B, RSV down-regulated
mRNA levels of both AR and its target gene PSA. This data
demonstrated that our experimental conditions and the effects of
RSV on LNCaP cells are similar to those previously reported.
Establishment of AR stable cell line AR(+)
In order to differentiate between the effects of RSV on AR
transcriptional activity from its effects on AR expression, we
wanted to establish a cell line in which AR expression is unaffected
by RSV. For this purpose, the AR open reading frame (ORF) was
first amplified by RT-PCR using mRNA purified from LNCaP
cells as template. Sequence analyses showed that neither XhoI nor
BamHI restriction site were in the ORF of AR. For cloning
purposes, we added the XhoI and BamHI sequences to the upper
and lower PCR primers, respectively. As shown in Figure 1A, the
amplified ORF of AR and the retroviral vector (pOZ-N) were
digested with XhoI and BamHI, and the ORF was cloned behind
the FLAG-tag. The virus was used to infect the AR-negative HeLa
cells. The expression of AR is controlled by the CMV promoter
and therefore the AR is expressed constitutively. This vector is also
capable of expressing the interleukin-2 receptor subunit (IL-2R,
Figure 2A) which serves as a surface marker for sorting of the
transduced cells. A population of AR(+) cells was selected by
repeated cycles of affinity cell sorting [37] using magnetic
Dynabeads M-450 (DYNAL, NY) coated with IL-2R antibodies.
Viruses containing empty pOZ-N vectors were used to infect
parental HeLa cells to generate AR(2) controls. Both AR(+) and
AR(2) cells were further screened by G148 and a population of
Figure 2. RSV Effects on LNCaP cells. (A) RSV inhibits LNCaP cell growth in a dose-dependent manner. Equal numbers of cells were seeded in
growth medium containing 10 nM R1881, and different concentrations of RSV as indicated. After 3 days of treatment, cells were collected and cell
numbers were determined. The numbers of cells in different RSV treatments were expressed as percentage of the control (0 uM RSV). The experiment
was conducted in triplicate and the averages were plotted and shown in (A). (B) RSV down-regulates the mRNA levels of AR and the AR target gene
PSA. Total RNA was isolated from cells treated with 50 mM of RSV for 3 days. AR and PSA mRNA levels were estimated by RT-PCR. In order to obtain
more accurate measurements, the internal control GAPDH was amplified together with genes of interest in the same PCR reaction.
doi:10.1371/journal.pone.0007398.g002
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cells, instead of individual clones, were used in the subsequent
experiments. Therefore, compared to the effects of AR expression,
the effects of random insertion of the virus DNA that could
potentially interrupt some endogenous genes would be minimal.
To verify that AR is specifically expressed in the AR(+) cell line,
western blots were conducted. Whole cell lysates were prepared
from both AR(+) and AR(2) cells, and equal amounts of total
protein were separated by electrophoresis on a 7.5% SDS-PAGE
gel. Antibodies against both AR and the FLAG-tag were used for
western blotting (Figure 2B). A single band corresponding to the
expected molecular weight of AR was shown only in the AR(+) cell
lysate, which is absent in the AR(2) cell lysate, when anti-AR
antibody was used. Although multiple bands were recognized by
the anti-FLAG antibody in both cell lines, the specific band
identified by the anti-AR antibody was only shown in the AR(+)
cells. The blots were stripped and re-probed by an antibody
against b-actin to demonstrate that equal amounts of proteins were
loaded in all lanes. All together, these data demonstrated that the
established AR(+) cells express AR specifically.
Characterization of AR in AR(+) cells
The first response of AR to androgen stimulation is dissociation
from heat shock protein complex and translocation to the nucleus
[10]. Since the AR is artificially pressed in the AR(+) cells, where
the cellular environment might not may not necessarily be
compatible with AR function, it is essential to demonstrate that
the artificially expressed AR behaves in a manner similar to the
endogenously expressed AR. Toward this end, we first wanted to
show that the constitutively expressed AR translocates to the
nucleus in response to androgens. Since both antibodies recognize
the Flag-tagged AR specifically (Figure 2B), we conducted
immunostaining assays with anti-Flag (Figure 3A) and anti-AR
(Figure 3B) of AR(+) cells with or without R1881 treatment. As
shown in Figure 3 (upper left panels), the majority of AR in AR(+)
cells was located in the cytosol before the addition of R1881.
However, after two hours of incubation with R1881 the AR was
mainly seen in the nucleus (upper right panels). The nuclei were
shown by DAPI staining (middle panels). The hormone-driven
translocation is more obvious when these images are superimposed
(lower panels). These results demonstrate that although the
subcellular environment in the AR(+) cells may not be identical
to that of the endogenous AR-expressing cells, the artificially
expressed AR still behaves similarly as the endogenous AR in
terms of hormone-driven translocation.
Next, we want to demonstrate that the artificially expressed AR in
the AR(+) cells possesses transcriptional activity. First, we conducted
a simple luciferase reporter assay. The plasmids containing the PSA-
enhancer cloned up-steam of the Luciferase gene were transiently
transfected to both AR(+) and AR(2) cells. Transfected cells were
allowed to recover for 6 hours before the synthetic androgen R1881
was added, and were then grown overnight. Luciferase activities in
the lysates from cells with different treatments were measured. As
shown in Figure 4A, the luciferase activity in the AR(+) cells
increased about seven times when the cells were treated with
R1881. As expected, this effect was not seen in the AR(2) cells,
where luciferase activity in R1881 treated cells was comparable to
that in the untreated cells. In addition, we estimated the hormone-
driven transcriptional activity by measuring the mRNA levels of a
few representative AR target genes. As shown in Figure 4B, similar
to that observed in the LNCaP cells, the levels of all the AR target
genes measured in this study increased significantly when the AR(+)
cells were treated with R1881. This demonstrated that the
overexpressed AR functions as a transcriptional factor in AR(+)
cells similar to that in prostate cancer cells.
In order to demonstrate that the above observed effects on AR
target gene expression were resulted from the expressed AR, we
compared the PSA mRNA levels in AR(+) and AR(-) cells with and
without hormone treatment. As shown in Figure 4C, the PSA level
was significantly elevated when the AR(+) cells were treated with
R1881 (right panel), and this hormonal effect was not seen in the
AR(2) cells (left panel). Although the PSA level in the untreated AR(+)
cells appears to be higher than those in the untreated AR(2) cells, the
Figure 3. Subcellular location of overexpressed AR. The AR(+) cells were treated for two hours with and without hormone R1881, and then
immunostained with anti-FLAG (A) or anti AR (B). Dapi staining shows the nuclei of the cells (middle panels). AR subcellular locations were shown by
the superimposed images (lower panels).
doi:10.1371/journal.pone.0007398.g003
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PSA/GAPDH ratios are comparable. One of the most important
steps in transcriptional regulation by AR is its recruitment to specific
DNA binding sequences known as androgen responsive element
(ARE) in the promoter/enhancer regions of its targets [10].
Chromatin immunoprecipipation (ChIP) assays were conducted to
demonstrate that the artificially expressed AR was recruited
specifically to its AREs when the cells were treated with R1881. Both
AR(+) and AR(2) cells were treated with R1881 and ChIP assays
were conducted with the anti-AR antibody as described in the
Materials and Methods. PCR was performed using primers specific to
the PSA enhancer region. As shown in Figure 4D, the AR was
specifically recruited to the PSA promoter/enhancer region when the
AR(+) cells were treated with R1881. This effect was not seen in the
AR(2) control cells. Together with the data from Figure 3, we
conclude that the artificially expressed AR not only translocates to the
nucleus when treated with hormone, but also functions as a hormone-
driven transcriptional factor in a manner similar to that of the
endogenously expressed AR.
RSV repression of AR transcriptional activity
AR expression in the AR(+) cells is controlled by the CMV
promoter and its expression is constitutive. This enables us to
analyze the effects of RSV on AR transcriptional activity without
interference from the changes in AR mRNA and protein levels. We
first conducted western blot to check the AR protein levels in AR(+)
cells after treatment with RSV. As shown in Figure 5A (upper
Figure 4. The overexpressed AR in AR(+) cells regulates its target gene expression in a hormone-dependent manner. (A) Luciferase
reporter assay. The luciferase reporter construct containing the PSA-enhancer region was transiently transfected into the AR(+) and AR(2) cells. After
a six-hour recovery, cells were treated with 10 nM of R1881 overnight. Luciferase activities in cell lystates with different treatments were measured
using the Promega kit. (B) RT-PCR. AR(+) and LNCaP cells were treated with 10 nM of R1881 overnight and total RNA was isolated. The mRNA levels of
representative AR target genes were measured with GAPDH as control. (C) RT-PCR. AR(+) and AR(2) cells were treated with 10 nM of R1881 overnight
and total RNA was isolated. The mRNA levels of PSA were measured with GAPDH as control. (D) ChIP assay. Both AR(+) and AR(2) cells were treated
with 10 nM of R1881 for two hours. DNA was fragmented by sonication and used for ChIP analysis using anti-AR antibody and the mouse IgG was
used as negative control. Precipitated DNA was amplified by PCR with primers specifically designed for the PSA enhancer region.
doi:10.1371/journal.pone.0007398.g004
Figure 5. RSV represses AR transcriptional activity without affecting AR protein levels. (A) The AR(+) cells were treated with either
different concentrations of RSV for 24 hours (Upper panel) or 50 uM of RSV for different periods of time (Bottom panel). Whole-cell lystates were
prepared and separated by electrophoresis on a 7.5% SDS-PAGE gel. Western blots were conducted with either anti-AR antibody or anti-actin
antibody for control. (B) RSV represses AR transcriptional activity. The reporter assay was conducted similarly as described in the legend of Figure 4A.
doi:10.1371/journal.pone.0007398.g005
Resveratrol, AR and Cancer
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panel), AR protein levels were indeed unchanged when the AR(+)
cells were treated with different concentrations of RSV for 24 hours.
However, we did notice that the cells appear unhealthy when
treated with higher concentrations of RSV (150 mM) for extended
time period. Since moderate levels of RSV have been used for most
of the reported research, we treated the AR(+) cells with 50 mM of
RSV for different lengths of time and found that moderate levels of
RSV treatment did not affect AR protein levels (Figure 5A, lower
panel). Therefore, this concentration (50 uM of RSV) was used in
subsequent experiments. RSV’s effects on AR transcriptional
activity were assessed by the luciferase reporter assay. The reporter
plasmid was transiently transfected to the AR(+) cells first, and the
cells were then allowed to recover for 6 hours. Cells were then
cultured overnight in medium with 10 nM of R1881 and 50 mM of
RSV. Similar to the data shown in Figure 4A, luciferase activity
measured from the whole cell lysate demonstrates that AR
transcriptional activity was about seven times higher when the cells
were treated with R1881 (Figure 5B). RSV treatment alone has no
effect on AR activity. However, RSV attenuated the R1881-
induced AR transcriptional activity by more than 50%.
Furthermore, we wanted to demonstrate that the effect of RSV
on AR transcriptional activity occurs by affecting AR-target gene
(PSA) expression. The AR(+) cells were cultured in medium with
10 nM of R1881 and 50 mM of RSV, and fractions of cells were
collected at different time points as indicated in Figure 6. Total
RNA was purified and used for RT-PCR with specific primers for
both AR and PSA. GAPDH served as an internal control. As
expected, AR mRNA levels did not change during the 32 hour
treatment but PSA mRNA levels decreased steadily in the AR(+)
cells (Figure 6A). When the same experiments were conducted
with the prostate cancer LNCaP cells, in which the AR expression
is affected by the intact AR promoter, both AR and PSA mRNA
levels decreased (Figure 6B). Noteworthy, the AR mRNA level was
not significantly reduced until the LNCaP cells were treated with
RSV for 16 hours, but the PSA mRNA levels decreased steadily,
with significant reduction seen when the cells were treated for only
Figure 6. RSV represses AR and AR target gene (PSA) expression through mechanisms other than nuclear translocation and AR
DNA binding. LNCaP cells (A) or AR(+) stable cells (B) were treated with RSV for different periods of time as indicated. Total RNA was isolated and
used as a template for RT-PCR to estimate the mRNA levels of AR and PSA. The intensities of the bands were quantified using the Image-J program
and results from three separated experiments were plotted on the right. (C) After two hours treatment, cells were detached from the plate by trypsin,
collected by centrifugation and suspended in culture medium. A fraction (about 30%) of the suspension was used for preparation of whole-cell lysate
(T), and the remainder was used for preparation of cytoplasmic (C) and nucleus (N) extracts. Equal amounts of proteins were separated on a 7.5%
SDS-PAGE gel, and western blots were performed using either anti-AR or anti-actin antibody. (D) Cells were treated with either R1881 or RSV alone or
in combination overnight as indicated. ChIP assays were conducted and PCR was done with specific primers.
doi:10.1371/journal.pone.0007398.g006
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8 hours. Altogether, these data demonstrated unambiguously that
RSV affects AR target gene expression, at least in part, by
repressing AR transcriptional activity.
Mechanisms of RSV repressive effects on AR
transcriptional activity
In order to understand the mechanisms of the RSV effects on
AR transcriptional activity, we examined the hormone-stimulated
nuclear translocation of AR with and without RSV treatment for
two hours. As shown in Figure 6C, without R1881 stimulation,
most AR protein resides in the cytoplasm; after two hours
treatment with R1881 most of AR protein was found in the
nucleus. RSV treatment itself did not affect AR subcellular
location. More importantly, treatment of cells with a combination
of R1881 and RSV did not affect hormone-induced AR nuclear
translocation. In addition, treatment of the AR(+) cells with R1881
and RSV did not affect AR protein levels. This further
demonstrated that in the AR(+) cells, AR is expressed constitu-
tively, and the effects of RSV on AR target gene expression are the
reflection of AR transcriptional activity. Next, we analyzed the
effects of RSV on AR/ARE interaction by ChIP assays. As shown
in Figure 6D, similar to that demonstrated in Figure 4C, the AR in
the AR(+) cells was successfully recruited to the ARE and the
recruitment is R1881 dependent (left panel). Surprisingly, R1881
stimulated AR recruitment was not affected by RSV treatment
although the AR transcriptional activity was reduced dramatically
by RSV treatment, as shown in Figure 5 and Figure 6A. These
results taken together suggest that the repressive effects of RSV on
AR transcriptional activity are through mechanisms other than by
affecting AR nucleus translocation or interrupting AR DNA
binding.
Discussion
Although it has been well established that RSV serves as a
potent chemopreventive reagent in several cancers including
prostate cancer, the underlying molecular mechanisms are largely
unknown [31]. Because of this and other reasons, RSV has not
been officially approved by the FDA as a dietary supplement for
cancer prevention purposes. It is important to delineate the
molecular mechanisms of chemopreventive effects of RSV on
cancers. In addition, because of its extremely long latency periods,
prostate cancer serves as an ideal model in chemoprevention
studies [6].
Similar to other cancers, prostate tumorigenesis develops with
complex etiologies. The chemopreventive effects of RSV on
prostate cancer are multi-faceted as well [27,31]. It is known that
RSV can induce prostate cancer cell apoptosis in a non-genomic
manner through the inhibition of the phosphoinositide-3-kinase
(PI3K) pathway [28]. However, because androgen and the
androgen receptor (AR) play pivotal roles in normal prostate
development and prostate tumorigenesis [10], special efforts have
been exerted to research the effects of RSV on AR. It is well
established that the chemopreventive effects of RSV on prostate
cancer involve its alteration of AR expression and function
[29,31]. RSV treatment of the AR positive cell line LNCaP
demonstrated that RSV down-regulates expression of both AR
and AR target genes [31,32]. Gao et al found that the effects of
RSV on AR activity are also concentration dependent; RSV
enhances AR activity at low concentrations and represses AR
activity at high concentrations [34]. Harada et al reported recently
that RSV represses AR target gene expression, at least partially, by
enhancing AR degradation in a time- and dose-dependent manner
[35]. Furthermore, AR is self-regulated and this further compli-
cates the regulation of AR expression. Therefore, the molecular
mechanisms about effects of RSV on AR and prostate cancer are
confusing.
In order to distinguish the effects of RSV on AR regulated gene
expression, we established an AR positive cell line, AR(+), from the
AR-negative HeLa cell line. The FLAG-tagged AR is recognized
by both AR and FLAG antibodies, and more importantly, the
overexpressed AR behaves in a manner similar to the AR
expressed endogenously (see below). However, since it is driven by
the strong cytomegalovirus (CMV) promoter [43], the expression
of AR in these cells is not affected by RSV treatment. Therefore,
both AR mRNA and protein levels are consistent during RSV
treatment (Figure 5 and 6). This enables us to estimate the effects
of RSV on AR transcriptional activity without the interference of
AR changes. Using this unique cellular model system, we
demonstrated that RSV modulates AR functions by affecting
AR transcriptional activity. However, this does not exclude the
other effects of RSV on AR and prostate cancer development
[10,44].
Since the parental cells used for the establishment of the AR(+)
cell line are not of prostate origin [45], it is essential to
demonstrate that the overexpressed AR functions in a manner
similar to the AR in its intact cellular environment. First, we
monitored the AR nuclear translocation by immunostaining.
Similar to the AR in the prostate cancer cell line LNCaP, and as
expected, the overexpressed AR in AR(+) cells treated with the
synthetic androgen R1881 translocated from the cytoplasm to the
nucleus (Figure 3). Second, by using both PSA-enhancer-Luc
reporter assay and RT-PCR to measure the endogenous PSA
mRNA levels we clearly demonstrated that the overexpressed AR
has hormone-dependent transcriptional activity (Figure 4). Fur-
thermore, all the representative AR target genes in the AR(+) cells
have responded to hormone treatment in a similar manner as that
in the LNCaP cells. More importantly, the hormone-dependent
effects were specifically observed in the AR(+) not the AR(2) cells
(Figure 4C). Finally, we were able to show that the overexpressed
AR binds DNA specifically (Figure 4D) and regulates the
expression of a target gene, presumably through the recruitment
of specific co-regulators such as SRC-1 [46]. Therefore, we
conclude that the overexpressed AR functions in a manner similar
to the endogenously expressed AR and that the established AR(+)
cell line can be used in studying AR functions without the
interference of variations in AR protein levels. More importantly,
AR(-) cells were established by transfecting the same parental cells
with the empty vector DNA. Theoretically, the only difference
between the AR(+) and AR(2) cells is that AR is expressed in the
AR(+) cells. Therefore, experiments with AR(2) cells as a negative
control will specifically elucidate the AR’s effects.
The AR(+) cells were made by transfecting the retroviral pOZ
vector containing the human AR open reading frame which is
integrated into the genome randomly. Insertion-induced interrup-
tions of certain endogenous genes are therefore unavoidable.
However, when a population of cells is used, the effects from the
insertion-induced interruption are minimal. Thus, results from
such experiments, especially when the AR(2) cells are used as a
negative control, should represent AR-mediated effects specifical-
ly. For the same reason, individual AR(+) cells or colonies derived
from individual AR(+) cells would not be recommended in
studying AR functions even if AR(2) cells are used as controls.
It is important to note that because the parental AR-negative
HeLa cells are not of prostate origin [45]. The cellular and
subcellular environment in the AR(+) cells would not be identical
to that in cells expressing endogenous AR. Although this new
model system will be useful in dissecting the molecular
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mechanisms of AR function, careful diligence is needed in
interpreting data obtained from using these cells alone. Alterna-
tively, it is practical to conduct experiments with both AR(+) cells
as well as cells expressing AR endogenously such as the LNCaP
call line. In our research, we simultaneously treated both the
AR(+) and LNCaP cells with the same concentrations of RSV.
The levels of AR protein and mRNA were repressed by RSV in
LNCaP but not in AR(+) cells. However, RSV represses PSA
expression in both cell lines (Figure 6). Given the effects of AR on
its target gene expression (Figure 4), we conclude that RSV
represses AR function, at least in part, by repressing AR
transcriptional activity.
We want to understand the molecular mechanisms underlying
the chemopreventive effects of RSV on prostate cancers, and to
apply this knowledge to further development of more potent
chemopreventive reagents. By using the unique AR(+) cell line, we
demonstrated that RSV amended the expression of AR target
genes by affecting AR transcriptional activity. This is consistent
with experiments using LNCaP cells [31,32]. Since RSV
treatment of the AR(+) cells affected neither AR nuclear
translocation nor the AR DNA binding, we proposed that RSV
affects AR transcriptional activity by either affecting AR
modification directly or altering the recruitment of AR cofactors
indirectly. It has been well established that AR transcriptional
activity is fine-tuned by different modifications such as phosphor-
ylation, acetylation, ubiquitylation and SUMOylation [47,48]. Fu
et al reported that SIRT1 plays essential roles in AR acetylation
status and inhibits AR transcriptional activity [49]. Recently, it has
been demonstrated that RSV up-regulates SIRT1 expression as
well as its enzymatic activity [50,51]. It will be intriguing to
explore the possibility that RSV affects AR transcriptional activity
by up-regulating SIRT2. Since AR recruits both co-activators and
co-repressors, Yoon and Wong proposed that the co-activator and
co-repressor ratio plays a rather important role in determining AR
transcriptional activity [13]. It is possible that RSV tempers AR
transcriptional activity, as well as AR target gene expression, by
altering the co-activator and co-repressor ratios on AR target gene
promoter/enhancer regions. Ultimately, modifications of histone
tails on the target promoter/enhancer regions are inevitable.
Thus, results from this research warrant further exploration of the
molecular mechanisms in RSV-mediated alterations of the histone
code and how they are involved in AR transcriptional regulation.
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